

FOR BODY DERMATOSES...

High-potency treatment that feels soothing on the skin^{1,2}



Patient-preferred emollient foam vehicle*^{1,2}



- For moderate to severe atopic dermatitis and mild to moderate psoriasis
- Ethanol-free and feels soothing on skin
- Easy to spread over multiple body areas

*Based on post-study surveys (N=377, N=376) of subjects using a 2-week BID regimen of OLUX-E Foam or vehicle foam for moderate to severe atopic dermatitis or mild to moderate plaque-type psoriasis.

Ordering information: OLUX-E 0.05%

50 g NDC# 63032010150

100 g NDC# 63032010100



Olux-ETM
(clobetasol propionate)
Foam, 0.05%

StiefelCareSM Value

- Provides Extensive Insurance Reimbursement Support for Patients. Call (800) 572-3225
- Assists Patients with Prior Authorizations
- Co-pay Assistance with Stiefel Rebate Card



INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR OLUX-E FOAM

OLUX-E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older.

Treatment should be limited to 2 consecutive weeks and patients should not use greater than 50 grams per week.

OLUX-E Foam has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

The pooled incidence of local adverse reactions in trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with OLUX-E Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

References: 1. Olux-E [package insert]. Coral Gables, Fla; Stiefel Laboratories, Inc.; 2006. 2. Data on File. August C. Stiefel Research Institute, Inc.

Please see accompanying full Prescribing Information.

STIEFEL, STIEFEL and the "S" logo, and the "V" logos are registered trademarks, VERSAFOAM-EF and OLUX-E are trademarks, and STIEFELCARE is a service mark of Stiefel Laboratories, Inc.

© 2007, Stiefel Laboratories, Inc. OLXE-40-2007-USA

